ONCT-534 showed a well-tolerated safety profile in mCRPC patients on a twice-daily dosing schedule, with no grade 3 or higher toxicities reported. Despite trial discontinuation, ONCT-534 demonstrated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results